Liraglutide
An earlier, daily-injection GLP-1 agonist sold as Saxenda (weight) and Victoza (diabetes), now largely eclipsed by weekly options.
Liraglutide was the proof of concept for GLP-1 weight treatment: approved as Victoza for type 2 diabetes in 2010 and as Saxenda for weight management in 2014. Chemically it hugs the natural hormone closely, which limits its half-life — hence daily rather than weekly injections.
Results are real but modest by current standards, with trials averaging roughly 5–8% body-weight loss versus about 15% for weekly semaglutide and more for tirzepatide. Generic liraglutide arrived in the mid-2020s, making it the budget injectable, though the daily needle and smaller averages mean most new patients start with newer molecules. It remains relevant for patients who tolerate it well or whose insurance favors it.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Liraglutide? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment